Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-β for use in malignant pleural mesothelioma: Heterogeneity in interferon responsiveness defines potential efficacy

Human Gene Therapy

Volumn 21, Issue 1, 2010, Pages 51-64

  Saloura, Vassiliki ^a   Wang, Liang Chuan S ^a   Fridlender, Zvi G ^a   Sun, Jing ^a   Cheng, Guanjun ^a   Kapoor, Veena ^a   Sterman, Daniel H ^a   Harty, Ronald N ^b   Okumura, Atsushi ^b   Barber, Glen N ^c   Vile, Richard G ^d   Federspiel, Mark J ^d   Russell, Stephen J ^d   Litzky, Leslie ^a   Albelda, Steven M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; DNA DEPENDENT PROTEIN KINASE; DOUBLE STRANDED RNA; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; PROTEIN P48; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PLEURA MESOTHELIOMA; RECEPTOR DOWN REGULATION; SCREENING; TUMOR BIOPSY; UPREGULATION; VIRUS RECOMBINANT;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; INTERFERON-BETA; MESOTHELIOMA; MICE; MICE, SCID; NEOPLASM PROTEINS; ONCOLYTIC VIROTHERAPY; PLEURAL NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VESICULOVIRUS; VIRAL LOAD; VIRUS REPLICATION;

ORTHOMYXOVIRIDAE; VESICULAR STOMATITIS VIRUS;

EID: 74949142894     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.088     Document Type: Article

References (40)

1. Ahmed, C.M.I., Johnson, D.E., Demers, G.W., Engler, H., Howe, J.A., Wills, K.N., Wen, S.F., Shinoda, J., Beltran, J., Nodelman, M., Machemer, T., Maneval, D.C., Nagabhushan, T.L., and Sugarman, B.J. (2001). Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xeno-graft models from a variety of cancers. Cancer Gene Ther. 8, 788-795.
2. Ahmed, M., Cramer, S.D., and Lyles, D.S. (2004). Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 330, 34-49.
3. Balachandran, S., and Barber, G.N. (2000). Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50, 135-138.
4. Balachandran, S., Porosnicu, M., and Barber, G.N. (2001). On-colytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75, 3474-3479.
5. Bergman, I., Griffin, J.A., Gao, Y., and Whitaker-Dowling, P. (2007). Treatment of implanted mammary tumors with re-combinant vesicular stomatitis virus targeted to Her2=neu. Int. J. Cancer 121, 425-430.
6. Brin, E., Atencio, I., Helmich, B.K., Maneval, D., and Laface, D. (2006). Adenovirus delivery provides extended interferon-alpha exposure and augments treatment of metastatic carcinoma. Cancer Gene Ther. 13, 664-675
7. Connell, N.D., and Rheinwald, J.G. (1983). Regulation of the cytoskeleton in mesothelial cells: reversible loss of keratin and increase in vimentin during rapid growth in culture. Cell 34, 245-253.
8. De Rienzo, A., Jhanwar, S.C., and Testa, J.R. (2000). Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes Cancer 28, 337-341. (Pubitemid 30399564)
9. Decker, T., Stockinger, S., Karaghiosoff, M., Muller, M., and Kovarik, P. (2002). IFNs and STATs in innate immunity to microorganisms. J. Clin. Invest. 109, 1271-1277.
10. Diaz, R.M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G., and Vile, R.G. (2007). Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67, 2840-2848.
11. Ebert, O., Harbaran, S., Shinozaki, K., and Woo, S.L. (2005). Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 12, 350-358.
12. Ebert, O., Shinozaki, K., Huang, T.G., Savontaus, M.J., Garcia-Sastre, A., and Woo, S.L. (2003). Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63, 3605-3611.
13. Huang, T.G., Ebert, O., Shinozaki, K., Garcia-Sastre, A., and Woo, S.L. (2003). Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol. Ther. 8, 434-440.
14. \+ T-cells are the key mediators of anti-tumor effects of the vascular disrupting agent 5,6 di-methylxanthe-none-4-acetic acid (DMXAA) in murine models of lung cancer and mesothelioma. Cancer Res. 65, 11752-11761.
15. Lichty, B.D., Power, A.T., Stojdl, D.F., and Bell, J.C. (2004). Vesicular stomatitis virus: re-inventing the bullet. Trends Mol. Med. 10, 210-216.
16. Linge, C., Gewert, D., Rossmann, C., Bishop, J.A., and Crowe, J.S. (1995). Interferon system defects in human malignant melanoma. Cancer Res. 55, 4099-4104.
17. Lun, X., Senger, D.L., Alain, T., Oprea, A., Parato, K., Stojdl, D., Lichty, B., Power, A., Johnston, R.N., Hamilton, M., Parney, I., Bell, J.C., and Forsyth, P.A. (2006). Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J. Natl. Cancer Inst. 98, 1546-1557.
18. Matin, S.F., Rackley, R.R., Sadhukhan, P.C., Kim, M.S., Novick, A.C., and Bandyopadhyay, S.K. (2001). Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res. 61, 2261-2266.
19. Murphy, J.E., and Rheinwald, J.G. (1997). Intraperitoneal injection of genetically modified, human mesothelial cells for systemic gene therapy. Hum. Gene Ther. 8, 1867-1879.
20. Nguyen, T., Abdelbary, H., Arguello, M., Breitbach, C., Leveille, S., Diallo, J.-S., Yasmeen, A., Bismar, T.A., Kirn, D., Falls, T., Snoulten, V.E., Vanderhyden, B.C., Werier, J., Atkins, H., Vaha-Koskela, M.J.V., Stojdl, D.F., Bell, J.C., and Hiscott J. (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc. Natl. Acad. Sci. USA 105, 14981-14986.
21. Obuchi, M., Fernandez, M., and Barber, G.N. (2003). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77, 8843-8856.
22. Odaka, M., Wiewrodt, R., DeLong, P., Tanaka, T., Zhang, Y., Kaiser, L., and Albelda, S. (2002). Analysis of the immunologic response generated by Ad.IFN-beta during successful intra-peritoneal tumor gene therapy. Mol. Ther. 6, 210-218.
23. Parato, K.A., Senger, D., Forsyth, P.A., and Bell, J.C. (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Canc. 5, 965-976.
24. Pfeffer, L.M., Wang, C., Constantinescu, S.N., Croze, E., Blatt, L.M., Albino, A.P., and Nanus, D.M. (1996). Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. J. Urol. 156, 1867-1871.
25. Power, A.T., Wang, J., Falls, T.J., Paterson, J.M., Parato, K.A., Lichty, B.D., Stojdl, D.F., Forsyth, P.A., Atkins, H., and Bell, J.C. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 15, 123-130.
26. Remmele, W., and Stegner, H.E. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for im-munohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathology 8, 138-140.
27. Russell, S.J. (2002). RNA viruses as virotherapy agents. Cancer Gene Ther. 9, 961-966.
28. Shinozaki, K., Ebert, O., Kournioti, C., Tai, Y.S., and Woo, S.L. (2004). Oncolysis of multifocal hepatocellular canrcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 9, 368-376.
29. Sterman, D.H., and Albelda, S.M. (2005). Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 10, 266-283.
30. Sterman, D.H., Gillespie, C.T., Carroll, R.G., Coughlin, C.M., Lord, E.M., Sun, J., Haas, A., Recio, A., Kaiser, L.R., Coukos, G., June, C.H., Albelda, S.M., and Vonderheide, R.H. (2006). Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat. Clin. Pract. Oncol. 3, 633-639.
31. Sterman, D.H., Recio, A., Carroll, R.G., Gillespie, C.T., Haas, A., Vachani, A., Kapoor, V., Sun, J., Hodinka, R., Brown, J.L., Corbley, M.J., Parr, M., Ho, M., Pastan, I., Machuzak, M., Benedict, W., Zhang, X.Q., Lord, E.M., Litzky, L.A., Heitjan, D.F., June, C.H., Kaiser, L.R., Vonderheide, R.H., Albelda, S.M., and Kanther, M. (2007). A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin. Cancer Res. 13, 4456-4466. (Pubitemid 47219714)
32. Stojdl, D.F., Lichty, B., Knowles, S., Marius, R., Atkins, H., So-nenberg, N., and Bell, J.C. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825.
33. Stojdl, D.F., Lichty, B.D., TenOever, B.R., Paterson, J.M., Power, A.T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., Brown, E.G., Durbin, R.K., Durbin, J.E., Hiscott, J., and Bell, J.C. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 4, 263-275.
34. Sun, W.H., Pabon, C., Alsayed, Y., Huang, P.P., Jandeska, S., Uddin, S., Platanias, L.C., and Rosen, S.T. (1998). Interfeon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 91, 570-576.
35. Sung, C.K., Choi, B., Wanna, G., Genden, E.M., Woo, S.L., and Shin, E.J. (2008). Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma. Laryngoscope 118, 237-242.
36. Wathelet, M.G., Lin, C.H., Parekh, B.S., Ronco, L.V., Howley, P.M., and Maniatis, T. (1998). Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol. Cell. 1, 507-518.
37. Willmon, C.L., Saloura, V., Fridlender, Z.G., Wongthida, P., Diaz, R.M., Thompson, J., Kottke, T., Federspiel, M., Barber, G., Albelda, S.M., and Vile, R.G. (2009). Expression of IFN-b enhances both efficacy and safety of oncolytic vesicular stomatitis virus (VSV) for therapy of mesothelioma. Cancer Res. 69, 7713-7720.
38. Wollmann, G., Robek, M.D., and van den Pol, A.N. (2007). Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J. Virol. 81, 1479-1491.
39. Wong, L.H., Krauer, K.G., Hatzinisiriou, I., Estcourt, M.J., Her-sey, P., Tam, N.D., Edmondson, S., Devenish, R.J., and Ralph, S.J. (1997). Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J. Biol. Chem. 272, 28779-28785.
40. Wu, Y., Lun, X., Zhou, H., Wang, L., Sun, B., Bell, J.C., Barrett, J.W., McFadden, G., Biegel, J.A., Senger, D.L., and Forsyth, P.A. (2008). Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin. Cancer Res. 14, 1218-1227.